Genes regulated by tyrosine kinase inhibitors
| Gene . | Accession no. . | Fold change (SD) . | |
|---|---|---|---|
| imatinib (32D/BCR-ABL) . | MLN518 (32D/FLT3-ITD) . | ||
| Genes induced by inhibitors | |||
| Topoisomerase-inhibitor suppressed | D86344 | 5.5 (0.3) | 6.7 (0.8) |
| Mad4 | U32395 | 4.3 (0.3) | 3.9 (0.2) |
| Cdk4 and Cdk6 inhibitor p19 | U19597 | 2.0 (0.2) | 2.1 (0.6) |
| Eyes absent 2 homolog | U81603 | 2.9 (0.6) | 2.9 (0.5) |
| Mnk2 | Y11092 | 2.1 (0.4) | 2.4 (0.3) |
| cyclin G2 | U95826 | 10.1(4.6) | 6.0 (2.2) |
| Mbd4 | AF072249 | 2.2 (0.1) | 1.7 (0.5) |
| Ecotropic viral integration site 2 | M34896 | 3.7 (1.3) | 2.8 (0.9) |
| G protein signaling regulator RGS2 | U67187 | 3.3 (1.3) | 6.5 (1.9) |
| Hemopoietic cell phosphatase | M68902 | 1.5 (0.2) | 2.2 (0.2) |
| Genes repressed by inhibitors | |||
| Cytokine inducible SH2-containing protein | D89613 | −7.0 (1.0) | −4.3 (0.6) |
| Inhibitor of DNA binding1 | M31885 | −49.0 (6.4) | −4.8 (0.9) |
| eIF-1A | AF026481 | −3.1 (0.6) | −3.1 (0.6) |
| Myelocytomatosis oncogene | L00039 | −11.8 (4.8) | −5.5 (0. 9) |
| Bcl2-like | L35049 | −3.2 (0.6) | −2.2 (0.3) |
| SIK similar protein | AF053232 | −2.6 (0.7) | −3.2 (0.6) |
| schlafen2 | AF099973 | −4.0 (0.5) | −2.8 (0.5) |
| cyclin D2 | M83749 | −7.0 (1.8) | −6.9 (1.7) |
| Proviral integration site 1 | M13945 | −7.8 (3.3) | −14.0 (2.9) |
| interleukin-4 receptor (secreted form) | M27960 | −2.2 (0.2) | −4.8 (0.5) |
| proliferation-associated protein 1 | U43918 | −2.6 (0.3) | −2.9 (0.6) |
| protein-serine/threonine kinase (pim-2) | L41495 | −5.0 (2.0) | −7.4 (1.3) |
| Gene . | Accession no. . | Fold change (SD) . | |
|---|---|---|---|
| imatinib (32D/BCR-ABL) . | MLN518 (32D/FLT3-ITD) . | ||
| Genes induced by inhibitors | |||
| Topoisomerase-inhibitor suppressed | D86344 | 5.5 (0.3) | 6.7 (0.8) |
| Mad4 | U32395 | 4.3 (0.3) | 3.9 (0.2) |
| Cdk4 and Cdk6 inhibitor p19 | U19597 | 2.0 (0.2) | 2.1 (0.6) |
| Eyes absent 2 homolog | U81603 | 2.9 (0.6) | 2.9 (0.5) |
| Mnk2 | Y11092 | 2.1 (0.4) | 2.4 (0.3) |
| cyclin G2 | U95826 | 10.1(4.6) | 6.0 (2.2) |
| Mbd4 | AF072249 | 2.2 (0.1) | 1.7 (0.5) |
| Ecotropic viral integration site 2 | M34896 | 3.7 (1.3) | 2.8 (0.9) |
| G protein signaling regulator RGS2 | U67187 | 3.3 (1.3) | 6.5 (1.9) |
| Hemopoietic cell phosphatase | M68902 | 1.5 (0.2) | 2.2 (0.2) |
| Genes repressed by inhibitors | |||
| Cytokine inducible SH2-containing protein | D89613 | −7.0 (1.0) | −4.3 (0.6) |
| Inhibitor of DNA binding1 | M31885 | −49.0 (6.4) | −4.8 (0.9) |
| eIF-1A | AF026481 | −3.1 (0.6) | −3.1 (0.6) |
| Myelocytomatosis oncogene | L00039 | −11.8 (4.8) | −5.5 (0. 9) |
| Bcl2-like | L35049 | −3.2 (0.6) | −2.2 (0.3) |
| SIK similar protein | AF053232 | −2.6 (0.7) | −3.2 (0.6) |
| schlafen2 | AF099973 | −4.0 (0.5) | −2.8 (0.5) |
| cyclin D2 | M83749 | −7.0 (1.8) | −6.9 (1.7) |
| Proviral integration site 1 | M13945 | −7.8 (3.3) | −14.0 (2.9) |
| interleukin-4 receptor (secreted form) | M27960 | −2.2 (0.2) | −4.8 (0.5) |
| proliferation-associated protein 1 | U43918 | −2.6 (0.3) | −2.9 (0.6) |
| protein-serine/threonine kinase (pim-2) | L41495 | −5.0 (2.0) | −7.4 (1.3) |
Murine 32Dcl3 cells transduced with BCR-ABL or FLT3-ITD were treated with either imatinib or MLN518 for 4 hours. Transcriptional profiles were analyzed using Affymetrix U74 oligonucleotide arrays. Data are from 3 independent experiments. Gene selection criteria: (1) Gene cluster software analysis showed P < .005. (2) Gene is among the top 200 most differentially expressed genes.
“Fold change” indicates the average change in gene expression between samples treated with specific inhibitors and samples treated with nonspecific inhibitors or without any inhibitors; and SD, standard deviation.